Cost-effectiveness of 4 neonatal screening strategies for cystic fibrosis

Pediatrics

Volumn 118, Issue 3, 2006, Pages 896-905

  Van Den Akker van Marle, M Elske ^a   Dankert, Hinke M ^a   Verkerk, Paul H ^a   Dankert Roelse, Jeannette E ^b  

^a TNO   (Netherlands)

^b Sittard Geleen Heerlen   (Netherlands)

Author keywords

Cost effectiveness; Economic evaluation; Neonatal; Screening newborn

Indexed keywords

DNA; TRYPSIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; ECONOMIC ASPECT; GEL ELECTROPHORESIS; GENE MUTATION; HUMAN; NETHERLANDS; NEWBORN SCREENING; PRIORITY JOURNAL; BLOOD; COST BENEFIT ANALYSIS; ECONOMICS; EVALUATION; GENETICS; IMMUNOASSAY; METHODOLOGY; NEWBORN; NUCLEOTIDE SEQUENCE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

COST-BENEFIT ANALYSIS; CYSTIC FIBROSIS; DNA MUTATIONAL ANALYSIS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; IMMUNOASSAY; INFANT, NEWBORN; NEONATAL SCREENING; TRYPSIN;

EID: 33749073438     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2005-2782     Document Type: Article

References (45)

1. Crossley JR, Elliott RB, Smith PA. Dried-blood spot screening for cystic fibrosis in the newborn. Lancet. 1979;1:472-474
2. Gregg RG, Simantel A, Farrell PM, et al. Newborn screening for cystic fibrosis in Wisconsin: comparison of biochemical and molecular methods. Pediatrics. 1997;99:819-824
3. Hammond KB, Abman SH, Sokol RJ, Accurso FJ. Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations. N Engl J Med. 1991;325:769-774
4. Massie RJ, Olsen M, Glazner J, Robertson CF, Francis I. Newborn screening for cystic fibrosis in Victoria: 10 years' experience (1989-1998). Med J Aust. 2000;172:584-587
5. Ranieri E, Lewis BD, Gerace RL, et al. Neonatal screening for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis: four years' experience. BMJ. 1994;308:1469-1472
6. Siret D, Bretaudeau G, Branger B, et al. Comparing the clinical evolution of cystic fibrosis screened neonatally to that of cystic fibrosis diagnosed from clinical symptoms: a 10-year retrospective study in a French region (Brittany). Pediatr Pulmonol. 2003;35:342-349
7. Wesley AW, Smith PA, Elliott RB. Experience with neonatal screening for cystic fibrosis in New Zealand using measurement of immunoreactive trypsinogen. Aust Paediatr J. 1989;25:151-155
8. Gezondheidsraad. Neonatale Screening. The Hague, Netherlands: Gezondheidsraad; 2005
9. Lee DS, Rosenberg MA, Peterson A, et al. Analysis of the costs of diagnosing Cystic Fibrosis with a newborn screening program. J Pediatr. 2003;142:617-623
10. Scotet V, Braekeleer M de, Roussey M, et al. Neonatal screening for cystic fibrosis in Brittany, France: assessment of 10 years' experience and impact on prenatal diagnosis. Lancet. 2000;356:789-794
11. Simpson N, Anderson R, Sassi F, et al. The cost-effectiveness of neonatal screening Cystic Fibrosis: an analysis of alternative scenarios using a decision model. Cost Eff Resour Alloc. 2005;3:8
12. Offerhaus PM, Anthony S, Oudshoorn CGM, Pal-de Bruin KVD, Buitendijk SE. Home Deliveries in the Netherlands. Final Report: 1995-2000; PG/JGD 2001.235. Leiden, the Netherlands: TNO Prevention and Health; 2002
13. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996
14. Ten Kate LP. Cystic Fibrosis in the Netherlands. Int J Epidemiol. 1977;6:23-34
15. Welsh MJ, Tsui LC, Boat TF, Beaudet AL. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease. 7th ed. New York, NY: McGraw-Hill, Inc; 1995:3799-3876
16. Mérelle ME, Schouten JP, Gerritsen J, Dankert-Roelse JE. Influence of neonatal screening and centralized treatment on long term outcome and survival of CF patients. Eur Respir J. 2001;18:306-315
17. Frederiksen B, Lanng S, Koch C, Høiby N. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol. 1996;21:153-158
18. Grosse SD, Boyle CA, Botkin JR, et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep. 2004;53(RR-13):1-36
19. Blankespoor MN, Lanting CI, Verkerk PH. Report of Screening on Congenital Hypothyroidism in Children Born in 2001 and Third Measurement 1996; PG/JGD 2002.260. Leiden, Netherlands: TNO Prevention and Health; 2002
20. Assael BM, Castellani C, Ocampo MB, Iansa P, Callegaro A, Valsecchi MG. Epidemiology and survival analysis of cystic fibrosis in an area of intense neonatal screening over 30 years. Am J Epidemiol. 2002;156:397-401
21. Comeau AM, Parad RB, Dorkin HL, et al. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics. 2004;113:1573-1581
22. Narzi L, Lucarelli M, Lelli A, et al. Comparison of two different protocols of neonatal screening for cystic fibrosis. Clin Genet. 2002;62:245-248
23. Mérelle ME, Scheffer H, de Jong D, Dankert-Roelse JE. Extended gene analysis can optimise newborn screening for cystic fibrosis. Acta Paediatr. 2006; In press
24. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr. 1998;132:589-595
25. Doull IJM, Ryley HC, Weller P, Goodchild MC. Cystic fibrosis-related deaths in infancy and the effect of newborn screening. Pediatr Pulmonol. 2001;31:363-366
26. Ferec C, Verlingue C, Parent P, et al. Neonatal screening for cystic fibrosis: result of a pilot study using both immunoreactive trypsinogen and cystic fibrosis gene mutation analysis. Hum Genet. 1995;96:542-548
27. Larsen J, Campbell S, Faragher EB, et al. Cystic fibrosis screening in neonates - measurement of immunoreactive trypsin and direct genotype analysis for ΔF508 mutation. Eur J Pediatr. 1994;153:569-573
28. Pederzini F, Faraguna D, Giglio L, Pedrotti D, Perobelli L, Mastella G. Development of a screening system for cystic fibrosis: meconium of blood spot trypsin assay or both. Acta Paediatr Scand. 1990;79:935-942
29. Roberts G, Stanfield M, Black A, Redmond A. Screening for cystic fibrosis: a four year regional experience. Arch Dis Child. 1988;63:1438-1443
30. Ryley HC, Deam SM, Williams J, et al. Neonatal screening for cystic fibrosis in Wales and the West Midlands: 1. Evaluation of immunoreactive trypsin test. J Clin Pathol. 1988;41:726-729
31. Wilcken B, Wiley V, Sherry G, Bayliss U. Neonatal screening for cystic fibrosis: a comparison of two strategies for case detection in 1.2 million babies. J Pediatr. 1995;127:965-970
32. Ranieri E, Lewis BD, Morris P, Wilcken B. Neonatal screening using combined biochemical and DNA-based techniques. In: Dodge JA, Brock DJM, Widdicombe JM, eds. Cystic Fibrosis: Current Topics. Vol. 3. New York, NY: John Wiley & Sons Ltd; 1996:182-206
33. Mastella G, Zanolla L, Castellani C, et al. Neonatal screening for cystic fibrosis: long-term clinical balance. Pancreatology. 2001;1:531-537
34. Dudding T, Wilcken B, Burgess B, Turner G. Neonatal screening for cystic fibrosis. Lancet. 2000;356:1930
35. Dudding T, Wilken B, Burgess B, Hambly J, Turner G. Reproductive decisions after neonatal screening identifies cystic fibrosis. Arch Dis Child Fetal Neonatal Ed. 2000;82:F124-F127
36. Scotet V, Audrezet MP, Roussey M, et al. Impact of public health strategies on the birth prevalence of cystic fibrosis in Brittany, France. Hum Genet. 2003;113:280-285
37. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH. Handbook for Costing Research, Methods and Guideline Prices for Economic Evaluations in Health [actualized version]. Amstelveen, Netherlands: Health Care Insurance Board; 2004
38. Wheeler PG, Smith R, Dorkin H, Parad RB, Comeau AM, Bianchi DW. Genetic counseling after implementation of statewide cystic fibrosis newborn screening: two years' experience in one medical center. Genet Med. 2001;3:411-415
39. National Health Tariffs Authority. National Health Tariffs. Utrecht, Netherlands: CTG; 2004
40. Kamp HJ van der, Otten BJ, Verkerk PH, Elvers LH, Loeber JG, Baarle W van, Verheul FEAM. Annual Report Pilot-Screening for Congenital Adrenal Hyperplasia 1998. Leiden, Netherlands: Leiden University Medical Center; 1999
41. Wildhagen MF. Cost and Effects of Genetic Screening With Application to Cystic Fibrosis and Fragile X Syndrome [thesis]. Rotterdam, Netherlands: Erasmus University; 1999
42. Dankert-Roelse JE, Mérelle ME. Review of outcomes of neonatal screening for Cystic Fibrosis versus non-screening in Europe. J Pediatr. 2005;147(3 suppl):S15-S20
43. Weijers-Poppelaars FAM, Wildhagen MF, Henneman L, Cornel MC, ten Kate LP. Preconception cystic fibrosis carrier screening: costs and consequences. Genet Test. 2005;9:158-166
44. Nielsen R, Gyrd-Hansen D. Prenatal screening for cystic fibrosis: an economic analysis. Health Econ. 2002;11:285-299
45. Sarles J, Berthezene P, Le Louarn C, et al. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis. J Pediatr. 2005;147:302-305